Sleep apnea is an important comorbidity in patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD). Although the increased prevalence of sleep apnea in patients with ESRD is well established, few studies have investigated the prevalence of sleep apnea in patients with nondialysis-dependent kidney disease, and no single study, to our knowledge, has examined the full spectrum of kidney function. We sought to determine the prevalence of sleep apnea and associated nocturnal hypoxia in patients with CKD and ESRD. We hypothesized that the prevalence of sleep apnea would increase progressively as kidney function declines.
Two hundred fifty-four patients were recruited from outpatient nephrology clinics and hemodialysis units. All patients completed an overnight cardiopulmonary monitoring test to determine the prevalence of sleep apnea (respiratory disturbance index ≥ 15) and nocturnal hypoxia (oxygen saturation < 90% for ≥ 12% of monitoring). Patients were stratified into three groups based on estimated glomerular filtration rate (eGFR) as follows: eGFR ≥ 60 mL/min/1.73 m(2) (n = 55), CKD (eGFR < 60 mL/min/1.73 m(2) not on dialysis, n = 124), and ESRD (on hemodialysis, n = 75).
The prevalence of sleep apnea increased as eGFR declined (eGFR ≥ 60 mL/min/1.73 m(2), 27%; CKD, 41%; ESRD, 57%; P = .002). The prevalence of nocturnal hypoxia was higher in patients with CKD and ESRD (eGFR ≥ 60 mL/min/1.73 m(2), 16%; CKD, 47%; ESRD, 48%; P < .001).
Sleep apnea is common in patients with CKD and increases as kidney function declines. Almost 50% of patients with CKD and ESRD experience nocturnal hypoxia, which may contribute to loss of kidney function and increased cardiovascular risk.
"with a declining kidney function. Of importance, in this study, diabetes was strongly associated with OSA and was a significant predictor of nocturnal hypoxemia . Schober and colleagues  examined the prevalence of OSA in 556 adults with diabetes (58 had type 1 diabetes) with an average diabetes duration of 9.3 AE 7.3 years (37.4% had an AH of !15 episodes/h) and found a higher prevalence of nephropathy in those with an AHI of !15 episodes/h. "
[Show abstract][Hide abstract] ABSTRACT: An increasing body of evidence suggests that obstructive sleep apnoea (OSA) is independently
associated with an increased risk of cardiovascular disease, glucose intolerance, and
deteriorations in glycaemic control. Despite the knowledge of a multifactorial pathogenesis
of long-term diabetes complications, there is a paucity of information on impact of
comorbidities associated with chronic intermittent hypoxemia on development and progression
of chronic diabetes complications. This review explores the clinical and scientific
overlap of OSA and type 2 diabetes mellitus (T2DM) and its possible impact on the development
and progression of diabetes macrovascular and microvascular complications.
Multiple prospective observational cohort studies have demonstrated that OSA significantly
increases the risk of cardiovascular disease independent of potential confounding
risk factors. The current evidence further suggests that OSA with concurrent T2DM is
associated with an increased risk of oxidative stress-induced damage of vulnerable
endothelial and mesangial cells and peripheral nerves. Further studies are needed to
validate the impact of OSA treatment on diabetes micro- and macrovascular complications.
Since it is presently still unknown whether OSA treatment may provide a diabetes-modifying
intervention that could delay or halt the progression of chronic diabetes complications,
the emphasis is on early diagnosis and satisfactory treatment of both OSA and T2DM.
Diabetes Research and Clinical Practice 05/2014; 104(2). DOI:10.1016/j.diabres.2014.01.007 · 2.54 Impact Factor
"Compared to subjects without nocturnal hypoxia, subjects with nocturnal hypoxia demonstrated an almost three-fold increase in the risk of accelerated loss of kidney function (Ahmed et al. 2011). However, there was also report that declining kidney function increased the prevalence of sleep apnea too (Nicholl et al. 2012). "
[Show abstract][Hide abstract] ABSTRACT: Obstructive sleep apnea causes cardiovascular disease via chronic intermittent hypoxia (IH), which may be related to oxidative stress. Nuclear factor-erythroid 2-related factor 2 (Nrf2) is an important cellular defense mechanism against oxidative stress by regulating its down-stream multiple antioxidants. The present study was to define whether IH can induce renal pathogenic damage and if so, whether Nrf2 and its down-stream antioxidants are involved in IH-induced pathogenic changes. Mice were culled for exposure to intermittent air as control or IH that consisted of 20.9% O2/ 8% O2 FIO2 alternation cycles (30 episodes per h) with 20 seconds at the nadir FIO2 for 12 h a day during daylight. Short-term IH exposure (3 - 7 days) induced significant increases in renal inflammatory response and antioxidant levels along with a reduction of the spontaneous content of malondialdehyde while long-term IH exposure (8 weeks) induced a significant decrease of antioxidant levels and significant increases of renal inflammation, oxidative damage, cell death, and fibrosis. This study suggests that IH induces a hormetic response, i.e.: short-term IH exposure is able to induce a protective response to protect the kidney from oxidative damage while long-term IH exposure is able to induce a damage effect on the kidney.
[Show abstract][Hide abstract] ABSTRACT: Die chronische Niereninsuffizienz ist ein starker kardiovaskulärer Risikofaktor. Nicht nur renale, sondern auch kardiale Schädigungen werden durch eine Mikroalbuminurie früh angezeigt. Eine optimale Blutdrucktherapie sowie Senkung der Proteinurie sind wichtige Maßnahmen zur Reduktion der deutlich erhöhten kardiovaskulären Morbidität und Mortalität bei diesem speziellen Kollektiv. Sowohl eine medikamentöse Sekundärprophylaxe als auch interventionelle Verfahren bei Vorliegen einer koronaren Herzerkrankung kommen bei Nierenkranken vielfach nur in unzureichendem Maße zum Einsatz. Patienten mit Niereninsuffizienz sollten zur Verbesserung des kardiovaskulären Outcomes auch großzügig auf das Vorliegen einer schlafbezogenen Störung untersucht und ggf. entsprechend behandelt werden. Prospektive Daten zu neuen Therapieansätzen wie oralen Faktor-Xa- oder Thrombininhibitoren bei Vorhofflimmern liegen nicht vor. Selbst für Vitamin-K-Antagonisten ist die Situation bei Dialysepatienten unklar. Auch Studien zur Transkatheteraortenklappenimplantation bei schwerer Aortenklappenstenose und fortgeschrittener Niereninsuffizienz oder Dialysepflichtigkeit fehlen bislang.
Der Internist 07/2012; 53(7). DOI:10.1007/s00108-011-3010-5 · 0.31 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.